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ABSTRACT
Background Substandard and falsified medical products are a public health threat, primarily associated with low- and middle-income
countries. Today, the phenomenon also exists in high-income countries. Increased Internet access has opened a global market. Self-diagnosis
and self-prescription have boosted the market for unregulated websites with access to falsified medicines.
Aim To describe the state of knowledge and experience on SF medical products among emergency physicians (EPs) and general practitioners
(GPs) in Sweden.
Methods An online survey with anonymous answers from 100 EPs and 100 GPs. Physicians were recruited from TNS SIFO’s medical database.
The term in the survey was ‘illegal and falsified medicines’ which was common in Sweden at that time. It corresponds well with the term
‘substandard and falsified medical products’ that the WHO launched shortly after our data collection. We report our results with this term.
Results In Sweden, 78.5% of the physicians had heard the term ‘illegal and falsified medicines’ and 36.5% had met patients they suspected
had taken it. Physicians lacked awareness of the use of the reporting system and wanted more knowledge about how to deal with patients
who have possibly used falsified medicines.
Conclusions To meet the public health threat of SF medical products, physicians need more knowledge.
Keywords drug abuse, emergency care, primary care
Introduction
The spread of substandard and falsified medical products is
a public health threat.1 Due to the low level of knowledge
about its scope and consequences, however, legal regulations
and penalties differ widely globally.2 Similarly, the definition
differs as to what is a spurious medical product. In May
2017, the World Health Organization (WHO) presented a
working definition aimed at specifying what may fall within
the scope of spurious medical products. WHO states that
medical products are to be referred to as substandard and
falsified (SF) medical products; substandard if they are
‘authorized medical products that fail to meet either their
quality standards or specifications, or both’, whereas falsified
medical products are ‘medical products that deliberately/
fraudulently misrepresent their identity, composition or
source’.3 In this article, we follow WHO’s definition of SF
medical products.
SF medical products can contain no active ingredient, an
inappropriate level of the active ingredient, or substances
inappropriate to consume.4 The direct danger is often the
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disease.1 The consequences are expected to be drug
resistance and lack of confidence in healthcare.5,6 In addition
to the problems associated with ineffective drugs, falsified
products sometimes contain toxic substances that can lead
to disability or death.1 According to WHO, both lifesaving
and lifestyle medicines, generic and branded medicines, are
targeted by falsifiers.7,8
SF medical products have primarily been associated with
low- and middle-income countries, but today the phenom-
enon also exists in high-income countries. The increased
Internet access has opened a global market.9 In many places,
such as in Europe and the USA, this seems to coincide with
a reorientation of the individual’s relationship with healthcare
system, and with the broader welfare state. A shift in
responsibility from the state to the individual has eroded
trust in the system and has led to a rise in self-care practices.
In Sweden, for example, much indicates that people are
increasingly looking for information about medicines on the
Internet, for example by asking other Internet users for
advice, instead of turning to doctors and pharmacies.10–13
As people’s attitudes to taking care of themselves have chan-
ged, and trust in authorities has diminished, the Internet has
taken the place as a site for health knowledge exchange and
the circulation of healthcare commodities, such as medicines.
This culture of self-diagnosis and self-prescription has
boosted the market for unregulated websites with access to
SF medical products.9–13 The controlled supply chain for
medicines between production and patients is long and com-
plex.14,15 Any weak link may enable the entrance of SF med-
ical products. In all regions of the world, SF medical
products have entered hospitals, clinics and pharmacies,
although SF medical products are more common on the
illegal market.15 SF medical products are by nature hard to
detect. The scope is based on estimations. Since there is little
validated data to underpin estimations of the scope, scale
and harm, the WHO in 2013 launched a global surveillance
and monitoring system.16 Africa accounts for the largest num-
ber of reports to WHO.17 The system, however, is under-
reported and research shows that reports do not correspond
to the actual situation in other regions such as Asia.18 Fairly
few reports exist from Europe17 of which two are from
Sweden.19 However, the problem is seen as very serious by
the Swedish Medical Products Agency (MPA). In order to
find out Swedish citizens’ views of online medicines, MPA
conducted an online survey in 2014 asking 2000 persons, ran-
domized and representative for the public, about their experi-
ences of buying prescription-only medicines online without
prescription. Only a few percent had done it but 40% were
considering doing so in the future. Over-represented groups
were younger people and people from urban environments.20
In addition, the Swedish MPA informs healthcare staff
about treatment recommendations. A published manual and
a website give guidelines on how doctors should act if SF
medical products are suspected. Healthcare staff should be
aware of and actively ask for a possible use of SF medical
products, primarily ordered online. Physicians are recom-
mended to advise patients not to buy medicines on illegal
websites and report any suspicion of adverse effects of med-
icines, including SF medical products.21
Aim
This study was conducted as a part of the interdisciplinary
project “Illegal drugs—information gathering from the gen-
eral public and physicians. A study for implementing knowl-
edge in society”. The project is a collaboration between the
Department of Arts and Cultural Science at the Faculties of
Humanities and Theology and the Faculty of Medicine at
Lund University, Sweden.22 The study is specifically aimed
at collecting data within the Swedish healthcare regarding SF
medical products.
In order to identify the scholarly knowledge regarding SF
medical products as well as gaps in the literature, researchers
in the project conducted a preliminary study in the form of a
literature review.23 With coded keywords, a search for aca-
demic journals published between 2000 and 2015 within all
the databases Lund University subscribes on the EBSCOhost
database platform was conducted. One identified gap is an
absence of empirical studies of the knowledge of SF medical
products among doctors and health staff, and how they
follow-up patients with unusual lack of medical efficacy or
unfamiliar medical side effects. We assumed that physicians
working in the first line on the healthcare as emergency physi-
cians (EPs) and general practitioners (GPs) would be most
exposed to the problem. Therefore, the aim of this study was
to gather information that could form a basis to describe the
state of knowledge and experience on SF medical products
among EPs and GPs.
Methods
We chose a survey with some questions with a mixed format
of multiple-choice and open-ended questions. In the survey,
we addressed the problem as ‘illegal and falsified medicines’,
which was the most common term used in Sweden at the
time of our survey in 2016. Over the years, there have been
a variety of definitions world wide of the phenomenon.2
This has complicated collaborations and discussions and is
one of the reasons why the WHO in 2017 proposed the
standardized term ‘substandard and falsified medical
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products’ (SF medical products).3 Although there are still
different opinions in the science communities, SF medical
products is the most internationally recognized term. It was
introduced the year after our survey while we were compil-
ing our data. In order to place our study within the frame-
work of ongoing discussions globally we chose to report the
results using the term SF medical products. The survey is
displayed in the Appendix. The quantitative analysis included
descriptive statistics of the multiple-choice questions. The
content of open-ended questions was categorized. No com-
parison of the Eps and the GPs was made since it was not
the purpose of the study.
The survey was constructed as an online survey with
anonymous answers from 100 specialists working as GPs
and 100 specialists working as EPs. The answers were col-
lected and presented to the research group by TNS SIFO,
an established Swedish market research institute. Physicians
were randomized and recruited from TNS SIFO’s medical
database. The medical database was built in 1985 and was
based on a commercial list of Swedish licensed physicians.
Physicians serving abroad, not entering their workplace
address or blocking their data are not included in this list.
Once the database was created TNS SIFO made the updates
themselves in order to ensure its relevancy. It is continually
updated to reflect the current treating physicians. The data-
base is not self-recruited.24
The respondents were recruited via e-mail. After recruit-
ment, a link with the questionnaire was sent to the respon-
dents. The physicians were introduced to the subject with
written information and answered online. To receive 100
answers from GPs, 260 GPs were randomly selected from
TNS SIFO’s medical database. The GPs were invited to par-
ticipate and the study closed after having obtained the first
100 answers. To receive 100 answers from physicians working
with emergency care, 900 physicians were randomly selected
from TNS SIFO’s medical database. To participate in the sur-
vey, the physicians had to confirm that they worked in emer-
gency medicine, thus excluding 74. The study was closed after
the first 100 answers were received from EPs. Physicians from
different medical specialties work in emergency care in Sweden
and the sample consisted of 37 internal medicine specialists,
25 psychiatrists, 18 lung specialists, 15 infection specialists, 1
surgeon, 1 specialist in emergency geriatrics, 1 anesthesiologist,
1 specialist in emergancy medicine and 1 specialist in general
practice. The answers were collected during May–June 2016.
Ethics
The survey study has been approved by the Regional Ethical
Review Board in Lund, registration number 2016/238.
Results
Survey background information
The group of EPs consisted of 68 males and 32 females
with a median age of 58 years. The group of GPs consisted
of 60 males and 40 females. Their median age was 60 years.
Survey results
Knowledge of the term
About four-fifths of the respondents (157/200) had heard of
the term ‘illegal and falsified medicines’ (reported here as sub-
standard and falsified medicines as explained above) before par-
ticipating in the survey. Among those who knew the term, the
leading source was media (137/157) such as daily newspapers
(96/137), medical journals (84/137) and television (76/137).
Other major sources were patient-related events at work
(50/157) and colleagues (48/157) (Table 1).
Meeting patients and suspecting SF medical products
Thirty-eight EPs and 35 GPs had personally met patients
who were suspected to have taken SF medical products. In a
free comment, EPs mentioned clues evenly from the med-
ical history and patients’ symptoms (21 vs. 17), while GPs
mainly received clues from the medical history (27 vs. 8).
Some comments hinted about the type of medicines they
suspected. The most common medicines were opioids and
benzodiazepines (14) followed by anabolic steroids (7).
Single comments also mentioned erectile dysfunction medi-
cine (2), treatment for hepatitis C (1), antibiotics (1) and
health products (1). In 47 comments, it was not possible to
specify what type of medicines was implied. Eleven com-
ments mentioned ordering online.
The informants were asked in an open-ended question
how they would act if they had a strong suspicion their
patient was taking SF medical products (Table 2). A majority
(129) gave answers that could be seen as trying to influence
the patients’ opinion and 10 physicians mentioned the possi-
bility of reporting to the Swedish Medical Products Agency.
Thirteen physicians gave an answer that might lead them to
more knowledge on how to act, mainly by talking to another
person within healthcare.
Unfamiliar medicines
A majority of the physicians (137) had encountered medi-
cines they did not recognize (Table 3). More than half (78/
137) were specified as foreign pharmaceuticals. The most
common types of medicines were antibiotics (33/137),
analgesics and NSAID (126/137), cardiovascular medicines
(19/137) and sedative and hypnotic medicines (13/137).
Most patients obtained the unfamiliar medicine abroad
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(105/139), or on the Internet (22/137). Common ways for
the physicians to act were to try to identify the medicine (56/
137), inform the patient about risks or counseling (42/137)
and to discourage the patient from the treatment (23/137).
The need for more knowledge
A majority of the physicians (157/200) expressed a need
more knowledge about SF medical products. In descending
order they favored written material such as newspaper arti-
cles and guidelines (109/157), lectures (76/157), or online
education (62/157) (Table 4).
In the open-ended questions of the survey, some physi-
cians addressed this want. One respondent wrote about the
difficulty of knowing what happens outside the regulated
medical system and stated, ‘I answer questions at the health-
care counseling hotline and it seems that some of them [lay-
persons] use [prescription-only] medicines they received in
other ways than by prescription from a physician’. Another
respondent pointed out the lack of knowledge of SF medical
products and emphasized that ‘the biggest issue is probably
that we are unaware of the scenario that patients might have
bought medicines this way [abroad or on the Internet]’.
Other respondents stressed the importance of learning more
about the problem and said that ‘it is frightening that an
unregulated online market exists with both potent and inef-
fective medicines’. The statements provide some examples
and point to a number of problems that may arise in the
wake of a growing unregulated medical market.
Table 1 Physicians’ knowledge of the term ‘illegal and falsified medicines’
EPs GPs
(n = 100) (%) (n = 100) (%)
Having knowledge of the term ‘illegal and falsified medicines’ 73 73 84 84
Type of source: (n = 73) (%) (n = 84) (%)
Media 62 85 75 89
Patient-related events at work 25 34 25 30
Colleagues 29 44 19 18
Private contacts 10 14 7 8
Others 5 5 5 6
Type of media: (n = 62) (%) (n = 75) (%)
Daily newspaper 46 74 50 67
Medical journal 37 60 47 63
TV 33 53 43 57
Social media 7 11 11 15
Others 6 10 2 3
Table 2 How physicians would act if suspecting that a patient takes SF medical products
EPs (n = 100) GPs (n = 100)
Inform the patient about the risks/talk with the patient 62 67
Advise against the use 21 14
Contact/report to different authorities, including the Medical Products Agency 14 5
Talk to colleagues/my manager 8 6
Take drug test/urine/send the drug for analysis 10 3
Issue new recipe/give the right medicine 8 3
Asks the patient to report to the police 4 4
Have not met any patient where there have been suspicions of SF medical products 2 5
Other 15 8
Do not know 4 6
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Table 3 Patients with medicines unfamiliar to the physicians
EPs GPs
(n = 100) (%) (n = 100) (%)
Physicians who had met patients with unfamiliar medicines 68 68 69 69
Type of medicines (n = 68) (%) (n = 69) (%)
Foreign pharmaceuticals 28 41 50 72
Antibiotics 13 19 20 29
Analgesics and antiphlogistics 13 19 13 19
Cardiovascular medicines 9 13 12 17
Sedative and hypnotic medicines 10 15 3 4
Vitamins, herbal remedies and health products 6 9 6 9
Other 21 31 18 26
Do not know 3 4 1 1
How the medicines were received (n = 68) (%) (n = 69) (%)
By doctor or pharmacy abroad 24 35 29 42
Abroad, unspecified 22 32 22 32
Internet 14 21 8 12
Doctor or pharmacist 4 6 7 10
Abroad in a store that was not a pharmacy 5 7 3 4
Other 10 15 7 10
Do not know 4 6 0 0
How physicians acted (n = 68) (%) (n = 69) (%)
Searched/googled/called the pharmacy to find out what kind of medicine it was 24 35 32 46
Informed the patient about the risk and counseling 21 31 21 30
Discouraged the patient from the treatment/medicines 13 19 10 14
Prescribed/change to the right medicine 8 12 12 17
Documented/recorded in the medical record 4 6 1 1
Recommended disposal of the medicines by the pharmacist 3 4 2 3
Other 5 7 4 6
Do not know 3 4 3 4
Table 4 Physicians’ opinions on the need for more knowledge
EPs GPs
(n = 100) (%) (n = 100) (%)
Physicians who need more knowledge about SF medical products
Yes 81 81 76 76
No 19 19 24 24
How physicians would like to obtain more knowledge (n = 81) (%) (n = 76) (%)
Written material (newspaper articles, guidelines etc.) 56 69 53 70
Lectures 45 56 31 41
Education online 32 40 30 39
Group discussions 8 10 7 9
In other way 2 2 2 3
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Discussion
Main findings of this study
This pilot study shows that a majority, but not all, of physicians
in emergency rooms and general practice were aware the term
SF medical products but few had knowledge of guidelines
including the appropriate use of the reporting system. A need
for more education was expressed by the physicians.
In this survey study, 21.5% of the participating physicians
had not heard the term SF medical products and the leading
source of information for those who had was the media.
The survey did not contain any information alternative such
as education or information from healthcare or authorities.
The participants could give this answer under ‘other source’,
an alternative selected by 10 of 157 physicians where this
type of source was the main source. Even if it is underesti-
mated, the number is far from the 137 physicians that
gained knowledge of the term from the media.
It is obvious from the results that a majority of the EPs
and the GPs were not familiar with current recommenda-
tions on actions when SF medical products are suspected.
The answers on how the physicians would act if they had a
strong suspicion their patient was taking SF medical pro-
ducts were compared with the recommendations from the
Swedish MPA. In accordance with the recommendations a
large proportion, 129 out of 200, mentioned conducting
advocacy work. However, many physicians did not mention
this. One possibility is that advising against the use of medi-
cines of unwarranted quality is so obvious that the physi-
cians did not even think of mentioning it in the survey. Only
10 out of 200 physicians answered that they would report a
strong suspicion of SF medical products to the MPA,
although this is recommended at any suspicion of an adverse
event. There is thus a potential for improvement when it
comes to communicating the issue of SF medical products
from the authorities to the treating physicians, including the
use of the reporting system.
The results show that EPs met more patients where the
patients’ symptoms led to suspicion. This is expected
because of the different patient clientele between emergency
and primary care.
In the survey, 78.5% were positive to the idea of gaining
more knowledge about SF medical products. The partici-
pants wanted to obtain information from written material
(newspaper articles, guidelines etc.) followed by lectures or
education online. Some written material exists,21,25 but there
might be a need for improvement of communicating the
written material to the physicians. The topic has received lit-
tle public interest in the media, which is also an important
source of information for physicians.
What is already known of this topic?
There is little knowledge about physicians’ awareness of SF
medical products. To our knowledge, this is the first study
of its kind in Sweden. Two Polish studies related to our
study can be found.26,27 They showed that 88.2% of the
physicians had faced a problem or heard of the SF medical
products or dietary supplements phenomenon,26 that 56.2%
of the physicians usually do not warn patients about SF
medical products27 and that 66.9% did not know the pro-
cedure for reporting suspicious medicine.27 Only 12 of 268
physicians had encountered complications caused by medi-
cines from unknown sources.27 However, the studies were
conducted in different circumstances with a different design
and did not have the same target group. Therefore, a direct
comparison cannot be made but both Swedish and Polish
physicians showed a need for further education in reporting
SF medical products.
What this study adds?
This study adds knowledge about a lack of awareness about
SF medical products and about the recommended reporting
system among physicians working in the first line of health-
care, primary and emergency care. It points to a need for
educational activities directed to physicians concerning this
global public health threat.
Limitations of this study
This study is part of a larger project concerning SF medical
products in Sweden and makes no comparisons between the
groups of physicians.22 Its purpose is to be descriptive in the
quantitative parts and present the physicians’ experiences.
The study prioritized obtaining a relatively large amount of
answers, set at 100 from each group. Through the choice of
method, there is possibility to generalize the result but some
parts of the method limit the generalizability. The partici-
pants were randomized from TNS SIFO’s medical database
which according to TNS SIFO reflects the current situ-
ation.24 Randomization promotes the generalizability of the
study. Some conscious choices were made that limited the
generalizability in order to obtain a rich material. Firstly, only
the first 100 answers were included, which limited the effect
of randomization. Secondly, for the EPs, specialists in emer-
gency medicine and internal medicine were targeted to get a
rich material since we assumed that these specialties had the
highest rate of taking care of patients with diffuse symp-
toms. To obtain 100 answers, the targets were widened to
nearby specialties. As a result, the composition of specialties
in our EPs group is unlikely to be representative of the com-
position of all physicians working in emergency care.
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As compared to figures from the Swedish National Board
of Health and Welfare, the responding GPs had a slightly
higher median age than the entire Swedish GP group (60
years vs. 56 years) and consisted of more male GPs (60%
vs. 54%).28 Older physicians may not be as well updated as
younger persons on new phenomena such as ordering drugs
online. That could distort the results and make the GPs
appear less knowledgeable. There is no obvious reason to
believe that gender should affect the result. Overall, we
assess that the known overrepresentation should not affect
the results in a major way. This kind of comparison could
not be done with the EPs since the group consisted of phy-
sicians from a variety of specialties.
Conclusion
In this study in general practice and emergency care in
Sweden, 78.5% of the physicians had heard about SF med-
ical products and 36.5% had met patients they suspected
had taken such medicines. The physicians lacked awareness
of the use of the reporting system when they suspected SF
medical products. To meet the Swedish Medical Products
Agency’s expected standard, the physicians need more
knowledge and they are positive to more education.
We want to clearly state that the term used in the survey
was ‘illegal and falsified medicines’ which was the concept
used in Sweden at the time of our data collection. The
WHO launch of the concept ‘substandard and falsified med-
ical products’, shortened to SF medical products, covers
what previously referred to in Sweden as ‘illegal and falsified
medicines’. Although there are still different opinions in the
science community about the term of the WHO, we see
great benefits and adhere to SF medical products.
The results of this study are being used in the larger pro-
ject about SF medical products and can be used by author-
ities to know how to relate to this fast-evolving issue, to
create educational material and as a basis for further studies.
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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